Geron Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Geron stock.
View analyst ratings for Geron or view top-rated stocks.

4 analysts have issued twelve-month price targets for Geron's stock. Their GERN stock forecasts range from $4.00 to $7.00. On average, they expect Geron's stock price to reach $5.50 in the next year. This suggests a possible upside of 301.5% from the stock's current price.
View analysts' price targets for Geron or view top-rated stocks among Wall Street analysts.

Geron's stock was trading at $1.22 at the beginning of the year. Since then, GERN stock has increased by 12.3% and is now trading at $1.37.
View the best growth stocks for 2022 here.

Geron is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Geron.

Geron Co. (NASDAQ:GERN) issued its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company earned $0.12 million during the quarter, compared to the consensus estimate of $0.10 million. Geron had a negative trailing twelve-month return on equity of 85.84% and a negative net margin of 8,584.92%. During the same period last year, the company posted ($0.09) earnings per share.
View Geron's earnings history.

5 employees have rated Geron CEO John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among Geron's employees.

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of GERN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), OrganiGram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.59%), Vanguard Group Inc. (4.59%), State Street Corp (3.58%), Northern Trust Corp (0.79%), Bank of New York Mellon Corp (0.36%) and Bank of America Corp DE (0.26%).
View institutional ownership trends for Geron.

GERN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Citigroup Inc., Bank of America Corp DE, Simplex Trading LLC, Northern Trust Corp, BNP Paribas Arbitrage SA, Group One Trading L.P., and GSA Capital Partners LLP.
View insider buying and selling activity for Geron or view top insider-selling stocks.

GERN stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, Renaissance Technologies LLC, Ergoteles LLC, Virtu Financial LLC, Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., and Mercer Global Advisors Inc. ADV.
View insider buying and selling activity for Geron or or view top insider-buying stocks.

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GERN stock can currently be purchased for approximately $1.37.

Geron (NASDAQ:GERN) has a market capitalization of $517.10 million and generates $1.39 million in revenue each year. The biopharmaceutical company earns $-116.11 million in net income (profit) each year or ($0.36) on an earnings per share basis.

Geron employs 69 workers across the globe.

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for Geron is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at [email protected], or via fax at 650-473-7750.